Coronary Allograft Vasculopathy (CAV)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Coronary Allograft Vasculopathy (CAV) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT06089486

MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading…

Canada576 participantsStarted 2024-01-08

Treatment: ICA, PET

All recent trials (14 shown)

CompletedPhase 2

NCT03944577

Impact of Evolocumab in Cardiac Transplant Patients With CAV

Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowerin…

United States26 participantsStarted 2019-07-15

Treatment: Evolocumab

CompletedPhase 4

NCT05373108

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

Many patients with end-stage heart failure, a condition in which the heart fails to pump enough blood to support the body's other organs, are fortunate enough t…

United States19 participantsStarted 2022-05-19

Treatment: Macitentan

Coronary Allograft Vasculopathy (CAV)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

All recent trials (14 shown)

Impact of Evolocumab in Cardiac Transplant Patients With CAV

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation

All recent trials (14 shown)

Impact of Evolocumab in Cardiac Transplant Patients With CAV

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients

Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy

Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the…

Assessment of Cardiac Allograft Vasculopathy by Optical Coherence Tomography

Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant

Severe CAV MRI in Heart Transplant Recipient

Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasc…

Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography